Dr. Raghav on Treatment Considerations in Metastatic CRC

Partner | Cancer Centers | <b>MD Anderson</b>

Kanwal Raghav, MBBS, MD, discusses treatment considerations in metastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment considerations in metastatic colorectal cancer (mCRC).

mCRC is managed with a wide variety of agents, Raghav says. Moreover, treatment selection is based on molecular profiling results and what disease subtype a patient has, Raghav explains. However, in most cases patients will receive first- and second-line treatment, followed subsequently by third-line treatment, Raghav says. Additionally, with some recent developments in the field, the definition of these treatment lines is broadening, Raghav adds.

Overall, most patients with mCRC will progress through their initial lines of therapy and reach a point where they are in need of a third-line regimen, which is also referred to as salvage therapy, Raghav concludes.